From physician dependency to SART data gaps, here are the six mistakes that sink fertility clinic deals — and how to avoid every one.
Find Vetted Fertility Clinic DealsFertility clinic acquisitions trade at 5–9x EBITDA and carry unique risks rooted in physician concentration, regulatory complexity, and publicly reported outcome data. Buyers who skip specialized due diligence routinely overpay or inherit liabilities that erode returns within 12 months of close.
Market Size
Approximately $8–9 billion in the U.S. as of 2024, with the global ART market exceeding $30 billion
Growth Trend
Growing
Recession Resistant
No
Market Structure
Moderately fragmented
Many fertility clinics generate 90%+ of revenue through one reproductive endocrinologist. If that physician leaves post-close without a strong employment agreement and earnout structure, patient volume can collapse within 90 days.
How to avoid: Require a 3–5 year physician employment agreement with non-compete before closing. Structure 15–25% of purchase price as an earnout tied to patient retention and EBITDA performance post-transition.
Publicly reported SART success rates are the primary driver of patient acquisition in fertility. Buyers who skip benchmarking a clinic's live birth rates against national averages miss the most important brand and revenue risk factor in the deal.
How to avoid: Pull three years of SART and CDC ART reports before LOI. Compare per-transfer live birth rates against national and regional averages. Below-average rates signal patient attrition risk post-acquisition.
An outdated IVF laboratory with aging incubators, micromanipulation systems, or vitrification equipment can require $500K–$1.5M in immediate capital replacement — costs rarely reflected in seller asking prices.
How to avoid: Commission an independent embryology laboratory audit before closing. Document equipment age, maintenance records, and remaining useful life. Factor replacement costs directly into your purchase price negotiation.
Most states prohibit non-physicians from owning medical practices outright. Buyers who acquire a fertility clinic without a properly structured MSO and Professional Services Agreement risk regulatory violations that can void the acquisition entirely.
How to avoid: Engage healthcare counsel with state-specific CPOM expertise before LOI. Confirm the MSO structure is compliant and that physician-owned PC agreements are properly documented and transferable.
Fertility clinic P&Ls frequently include above-market physician compensation, personal expenses, and one-time revenue items that inflate stated EBITDA. Paying 7x on inflated earnings is a fast path to a failed deal.
How to avoid: Require a third-party Quality of Earnings report normalizing physician compensation to market rates and removing non-recurring items. Never base purchase price on seller-prepared financials alone.
A clinic heavily reliant on a single employer fertility benefit contract or state mandate reimbursement faces revenue concentration risk. Policy changes or contract non-renewals can eliminate 30–40% of revenue overnight.
How to avoid: Analyze three years of payer mix data. Confirm employer and Progyny or WINFertility contract terms, renewal dates, and exclusivity clauses. Prioritize clinics with diversified self-pay and multi-payer revenue.
Buyers submit SBA loan applications before independently verifying the Fertility Clinic's normalized EBITDA. When diligence reveals add-backs that don't hold, the deal's debt service coverage collapses and the loan fails underwriting.
How to avoid: Build your EBITDA model with conservative add-back assumptions before engaging an SBA lender. At current rates, a $1M SBA 7(a) loan costs approximately $13,000/month — the Fertility Clinic needs $195,000+ in post-salary EBITDA to clear 1.25x DSCR.
Buyers close on a Fertility Clinic assuming operations transfer smoothly, then discover undocumented processes, informal vendor relationships, and staff who rely on institutional knowledge the seller carries in their head.
How to avoid: Require a 60-day operational documentation period before closing. Walk through every key process with the seller present, document staff responsibilities, vendor contacts, and customer communication protocols. Build a 90-day integration plan before the wire hits.
What experienced buyers verify before committing to a Fertility Clinic acquisition.
The specific concerns and miscalculations buyers face in this industry.
Common miscalculations sellers make that reduce their final price or derail a deal.
No. Fertility clinics are not SBA-eligible due to their medical practice classification. Buyers typically use private equity capital, seller financing, or healthcare-focused lenders to fund acquisitions.
Established SART-member clinics with above-average success rates and multiple REs trade at 6–9x EBITDA. Single-physician clinics with average outcomes typically command 5–6x given higher transition risk.
An MSO allows a non-physician entity to own management and operational assets while a physician-owned PC retains clinical control, maintaining compliance with state corporate practice of medicine laws.
Buyers most often skip embryology lab audits and HIPAA compliance reviews of embryo disposition consents — two areas that can generate significant post-close liability if overlooked during diligence.
More Fertility Clinic Guides
DealFlow OS helps you find and evaluate acquisitions with seller signals and due diligence tools. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers